Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

Analysis of Short-term (Operating) Activity Ratios 
Quarterly Data

Microsoft Excel

Short-term Activity Ratios (Summary)

Johnson & Johnson, short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Turnover Ratios
Inventory turnover 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77 2.87 2.86 2.91 2.86 3.04
Receivables turnover 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08 6.14 6.13 6.00 5.64 6.08
Payables turnover 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26 2.70 3.32 3.38 3.34 2.99
Working capital turnover 284.99 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 4.88 5.02 5.57 5.95 5.97 5.93 7.26 9.44
Average No. Days
Average inventory processing period 168 163 165 169 166 158 154 149 164 155 147 136 136 132 127 128 125 128 120
Add: Average receivable collection period 72 65 61 67 67 64 64 62 68 65 62 60 62 60 59 60 61 65 60
Operating cycle 240 228 226 236 233 222 218 211 232 220 209 196 198 192 186 188 186 193 180
Less: Average payables payment period 119 123 137 120 121 113 132 111 133 120 137 118 116 112 135 110 108 109 122
Cash conversion cycle 121 105 89 116 112 109 86 100 99 100 72 78 82 80 51 78 78 84 58

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).


Inventory Turnover
The inventory turnover ratio shows a declining trend over the observed periods, starting around 3.04 and gradually decreasing to approximately 2.17 by the latest quarter. This suggests a slower movement of inventory, indicating that inventory is being held longer before sale.
Receivables Turnover
Receivables turnover generally exhibits some fluctuations but overall shows a slight downward trend from about 6.08 to near 5.08. This implies a moderately slower collection of receivables, potentially indicating an elongation in the credit period granted to customers or difficulties in collection.
Payables Turnover
Payables turnover fluctuates without a strong directional trend, ranging mostly between 2.66 and 3.38. Periodic increases and decreases suggest variability in the payment behavior to suppliers but no sustained acceleration or deceleration is evident.
Working Capital Turnover
The working capital turnover ratio displays significant variability. Early periods show moderate levels near 5.0 to 7.3, followed by extreme spikes, such as a notable peak at 284.99 in one quarter. These large jumps may indicate unusual operational or accounting events impacting the efficient use of working capital.
Average Inventory Processing Period
The average inventory processing period steadily increases from around 120 days to approximately 168 days. This reinforces the observation from inventory turnover, indicating inventory remains longer in stock before being sold.
Average Receivable Collection Period
The average receivable collection period varies somewhat but shows an overall gradual increase from about 60 days to 72 days. This aligns with receivables turnover trends, suggesting slower customer payment patterns over time.
Operating Cycle
The operating cycle lengthens from roughly 180 days to about 240 days, indicating a longer duration between the acquisition of inventory and receipt of cash from sales, possibly due to increasing inventory holding and receivable collection times.
Average Payables Payment Period
The average payables payment period shows irregular movements, ranging from approximately 108 to 137 days. The absence of a clear trend reflects varying supplier payment strategies without consistent acceleration or delay tendencies.
Cash Conversion Cycle
The cash conversion cycle fluctuates notably, initially rising from 58 days to around 116 days before varying between 89 and 121 days in later quarters. These fluctuations suggest changes in cash flow timing related to inventory, receivables, and payables management, with a tendency toward elongation of the period during which cash is tied up in operations.

Turnover Ratios


Average No. Days


Inventory Turnover

Johnson & Johnson, inventory turnover calculation (quarterly data)

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Cost of products sold 7,628 7,357 7,128 6,963 6,869 6,511 6,798 6,606 6,462 6,687 7,765 7,807 7,919 7,598 7,955 7,250 7,587 7,063 7,814 6,972 6,579 7,062
Inventories 13,412 12,659 12,444 12,603 12,169 11,383 11,181 11,198 12,888 12,809 12,483 11,675 11,437 10,990 10,387 10,387 10,100 9,952 9,344 9,599 9,424 8,868
Short-term Activity Ratio
Inventory turnover1 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77 2.87 2.86 2.91 2.86 3.04
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. 3.71 4.04 4.09 4.86 4.83 4.98 4.74 4.30 4.53 4.87 5.54 4.99 4.96 5.58 5.76 5.45 5.40 4.65
Amgen Inc. 1.88 1.84 1.75 1.42 1.14 0.89 1.41 1.38 1.31 1.30 1.34 1.40 1.48 1.58 1.53 1.53 1.53 1.58
Bristol-Myers Squibb Co. 5.18 5.28 5.46 3.57 3.72 3.70 4.02 4.33 4.39 3.93 4.33 4.77 4.59 4.55 4.74 4.85 5.01 5.61 5.68
Danaher Corp. 3.60 3.79 4.15 3.60 3.59 3.73 3.80 3.53 3.58 3.50 4.03 3.80 3.71 3.87 4.16 4.06 4.28 4.34 4.28
Eli Lilly & Co. 0.96 1.11 1.05 1.16 1.17 1.23 1.40 1.37 1.36 1.54 1.86 1.79 1.93 1.88 1.79 1.80 1.68 1.38
Gilead Sciences Inc. 3.55 3.66 3.62 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50 4.08 3.21 2.99 2.79 2.72
Merck & Co. Inc. 2.43 2.49 2.45 2.39 2.42 2.54 2.63 2.66 2.72 2.95 3.10 3.06 2.74 2.29 2.73 2.79 2.40 2.45
Pfizer Inc. 1.60 1.65 1.66 2.05 2.15 2.45 2.65 2.31 3.07 3.82 3.62 3.66 3.67 3.40 2.78 1.80 1.28 1.08
Regeneron Pharmaceuticals Inc. 0.63 0.64 0.64 0.65 0.66 0.70 0.72 0.69 0.67 0.65 0.83 0.96 1.27 1.25 0.88 0.82 0.56 0.58
Thermo Fisher Scientific Inc. 4.82 5.06 4.62 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87 3.88 3.90 4.03 4.01 4.02
Vertex Pharmaceuticals Inc. 1.14 1.27 1.37 1.53 1.65 1.71 1.71 1.90 2.06 2.35 2.69 2.70 2.83 2.56 2.58 2.52 2.56 2.62

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q2 2025 Calculation
Inventory turnover = (Cost of products soldQ2 2025 + Cost of products soldQ1 2025 + Cost of products soldQ4 2024 + Cost of products soldQ3 2024) ÷ Inventories
= (7,628 + 7,357 + 7,128 + 6,963) ÷ 13,412 = 2.17

2 Click competitor name to see calculations.


The cost of products sold demonstrates variability over the observed periods with a general upward tendency from early 2024 onward. Initially, the cost fluctuated between approximately 6,500 and 8,000 million US dollars, with peaks near the end of calendar years 2020 and 2021. Following a decline in mid-2023, costs began increasing again by the first quarter of 2024, reaching higher levels by mid-2025.

Inventories showed a steady increase across the timeline, moving from around 8,800 million US dollars in early 2020 to over 13,000 million US dollars by mid-2025. The inventory level experienced consistent growth with some minor fluctuations, particularly a slight reduction between late 2023 and early 2024 before continuing its upward trajectory.

The inventory turnover ratio, starting from the measurement available in late 2020, generally declined over the periods analyzed. Initially above 3.0, the ratio gradually decreased to values near 2.15 by the second quarter of 2025, suggesting a slower rate of inventory turnover. This decline indicates an increasing amount of inventory held relative to the cost of products sold, which could imply potential challenges in inventory management or changes in sales velocity.

Cost of Products Sold
Shows periodic fluctuations with peak values typically at year-end dates; an upward trend resumes in early 2024 projecting into 2025.
Inventories
Exhibits a consistent upward trend throughout the entire period, growing by more than 50% from early 2020 to mid-2025, indicative of expanding stock levels.
Inventory Turnover Ratio
Displays a declining pattern from over 3.0 in late 2020 to around 2.15 by mid-2025, reflecting a slower inventory movement relative to sales.

Overall, the data indicates increasing costs and inventory levels with a decreasing turnover rate, potentially signaling a buildup of inventory relative to sales activity. This dynamic may warrant further analysis into inventory management effectiveness and sales trends.


Receivables Turnover

Johnson & Johnson, receivables turnover calculation (quarterly data)

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Sales to customers 23,743 21,893 22,520 22,471 22,447 21,383 21,395 21,351 21,519 20,894 23,706 23,791 24,020 23,426 24,804 23,338 23,312 22,321 22,475 21,082 18,336 20,691
Accounts receivable, trade, less allowances 17,846 16,020 14,842 16,174 15,794 14,946 14,873 14,798 16,777 16,350 16,160 15,890 16,139 15,594 15,283 14,911 14,871 14,938 13,576 14,579 14,645 14,874
Short-term Activity Ratio
Receivables turnover1 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08 6.14 6.13 6.00 5.64 6.08
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 4.60 5.16 4.84 4.69 4.55 4.87 4.83 4.88 4.95 5.16 5.38 5.10 5.29 5.63 5.94 5.42 5.24 5.19
Amgen Inc. 4.03 4.72 4.26 4.26 4.16 3.70 4.17 4.34 4.34 4.46 4.60 4.62 4.81 4.96 5.11 5.39 5.41 5.36
Danaher Corp. 6.74 6.79 6.75 6.77 7.15 7.02 6.09 6.15 6.64 6.89 6.40 7.09 6.81 6.87 6.36 6.69 6.51 6.28 5.51
Eli Lilly & Co. 4.07 4.09 3.97 3.53 4.56 3.75 3.93 3.93 3.68 4.14 4.35 4.57 4.64 4.24 4.69 4.58 4.56 4.18
Gilead Sciences Inc. 6.51 6.47 6.14 5.92 5.84 5.78 5.68 6.43 6.43 5.65 6.16 6.60 7.18 6.01 5.95 6.34 6.43 4.98
Merck & Co. Inc. 5.92 6.24 5.55 5.37 5.40 5.81 5.71 5.29 5.56 6.27 6.22 5.93 5.49 5.28 5.56 6.00 5.65 6.11
Pfizer Inc. 5.27 5.55 4.18 4.93 5.09 5.33 6.25 7.66 7.57 9.16 6.21 6.68 6.99 7.08 5.81 5.23 4.70 5.28
Regeneron Pharmaceuticals Inc. 2.53 2.29 2.27 2.36 2.51 2.31 2.35 2.47 2.42 2.28 2.47 2.76 3.41 2.66 2.48 1.77 2.20 2.07
Thermo Fisher Scientific Inc. 5.07 5.23 5.13 5.33 5.36 5.21 5.19 5.43 5.53 5.53 5.76 5.53 5.21 4.92 7.03 6.99 6.46 5.61
Vertex Pharmaceuticals Inc. 6.15 6.85 6.07 6.24 5.68 6.31 6.27 6.11 5.95 6.19 6.28 6.26 6.15 6.66 6.48 7.19 6.56 7.01

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q2 2025 Calculation
Receivables turnover = (Sales to customersQ2 2025 + Sales to customersQ1 2025 + Sales to customersQ4 2024 + Sales to customersQ3 2024) ÷ Accounts receivable, trade, less allowances
= (23,743 + 21,893 + 22,520 + 22,471) ÷ 17,846 = 5.08

2 Click competitor name to see calculations.


The quarterly financial data reveals several notable trends in sales, accounts receivable, and receivables turnover over the analyzed periods.

Sales to customers
Sales figures exhibit moderate fluctuations across the quarters. Initially, there was a decline from US$20,691 million in March 2020 to US$18,336 million in June 2020, followed by a recovery and gradual growth to a peak of approximately US$24,804 million by December 2021. Sales subsequently decreased slightly during early 2022 but demonstrated some variability in later quarters, fluctuating between roughly US$20,800 million and US$23,700 million. The data indicates no sustained upward or downward trend in recent quarters, suggesting relative stabilization with periodic fluctuations.
Accounts receivable, trade, less allowances
Accounts receivable show a general upward trend over the periods analyzed. Starting at US$14,874 million in March 2020, receivables gradually increased, reaching US$16,160 million by December 2022. A notable rise is observed in the more recent quarters, with values climbing to US$17,846 million by June 2025. The increase in receivables outpaces the more stable sales volumes in some periods, which could imply lengthening collection cycles or changes in credit terms.
Receivables turnover ratio
The receivables turnover ratio, available from September 2020 onward, demonstrates a declining trend. Initially, the ratio stood above 6, indicating strong efficiency in collecting receivables relative to sales. Over subsequent quarters, the ratio gradually fell to just above 5 by mid-2025. This decline suggests that the company may be taking longer to collect its receivables or that receivables are increasing at a faster pace than sales, which aligns with the observed growth in accounts receivable balances.

Overall, while sales volumes showed recovery and relative stability after the initial pandemic-related dip, the combination of steadily increasing accounts receivable and a declining receivables turnover ratio indicates a potential decrease in collection efficiency. This trend merits further examination to determine whether it results from changing customer payment behavior, credit policies, or other operational factors.


Payables Turnover

Johnson & Johnson, payables turnover calculation (quarterly data)

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Cost of products sold 7,628 7,357 7,128 6,963 6,869 6,511 6,798 6,606 6,462 6,687 7,765 7,807 7,919 7,598 7,955 7,250 7,587 7,063 7,814 6,972 6,579 7,062
Accounts payable 9,464 9,545 10,311 8,954 8,848 8,174 9,632 8,355 10,443 9,909 11,703 10,153 9,765 9,309 11,055 8,961 8,704 8,503 9,505 7,044 6,765 7,411
Short-term Activity Ratio
Payables turnover1 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26 2.70 3.32 3.38 3.34 2.99
Benchmarks
Payables Turnover, Competitors2
Amgen Inc. 5.25 6.74 5.99 5.01 6.10 5.32 5.22 5.67 4.97 4.08 5.30 5.09 4.65 4.72 5.41 4.92 4.40 4.33
Bristol-Myers Squibb Co. 2.61 3.52 3.88 3.43 3.05 3.12 3.28 3.75 3.38 3.20 3.33 3.82 3.41 3.25 3.37 3.89 2.97 3.69 4.34
Danaher Corp. 5.62 5.57 5.52 6.04 5.84 5.88 5.58 5.63 5.82 5.68 5.45 5.61 5.00 5.04 4.48 5.20 5.54 5.29 4.79
Eli Lilly & Co. 2.61 2.61 2.70 2.56 2.88 2.73 2.81 2.65 3.07 3.43 4.24 4.21 5.24 4.38 4.46 4.30 3.75 3.41
Gilead Sciences Inc. 8.47 7.50 7.49 12.57 10.69 11.81 9.90 9.06 8.99 6.25 11.22 11.89 11.43 9.36 9.18 8.70 8.71 5.42
Merck & Co. Inc. 3.98 3.72 4.26 4.39 4.48 4.11 4.59 4.58 4.34 4.08 5.16 4.86 4.25 2.96 4.54 3.93 3.81 3.37
Pfizer Inc. 3.30 3.17 3.67 4.60 4.19 3.72 5.07 3.92 4.78 5.04 5.49 6.17 6.66 5.53 5.11 3.72 2.68 2.02
Regeneron Pharmaceuticals Inc. 2.84 2.50 3.87 3.32 2.67 2.99 3.43 3.14 2.69 2.65 3.74 4.00 5.39 4.32 4.23 3.42 2.23 2.36
Thermo Fisher Scientific Inc. 8.25 8.18 9.63 9.85 9.91 8.97 10.41 10.82 9.35 7.67 9.93 8.84 7.96 6.83 8.31 8.88 8.12 7.45
Vertex Pharmaceuticals Inc. 3.49 3.71 3.73 4.27 3.81 3.46 3.13 3.16 3.41 3.55 8.23 5.01 5.52 4.64 6.73 6.35 5.99 4.75

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q2 2025 Calculation
Payables turnover = (Cost of products soldQ2 2025 + Cost of products soldQ1 2025 + Cost of products soldQ4 2024 + Cost of products soldQ3 2024) ÷ Accounts payable
= (7,628 + 7,357 + 7,128 + 6,963) ÷ 9,464 = 3.07

2 Click competitor name to see calculations.


The quarterly financial data reveals several notable trends in Johnson & Johnson's cost of products sold, accounts payable, and payables turnover ratios over the analyzed periods from March 2020 through June 2025.

Cost of Products Sold

The cost of products sold exhibits considerable fluctuations over the timeline. Initially, there is a decline from $7,062 million in March 2020 to $6,579 million in June 2020, followed by a rise to $7,814 million in December 2020. The metric then fluctuates moderately through 2021 and 2022 with peaks around $7,919 million in July 2022 and troughs near $6,462 million in July 2023.

From the end of 2022 into 2023 and 2024, a relatively stable but slightly upward trend is observed, with the cost reaching $7,628 million by June 2025. Seasonal or periodic variations appear pronounced, but overall, the cost of goods sold remains within a range of approximately $6,400 million to $7,900 million, indicating some variability but no strong sustained growth or decline.

Accounts Payable

Accounts payable has shown overall growth with significant variation between quarters. Starting at $7,411 million in March 2020, there was a noticeable increase peaking at $11,703 million in December 2021. After this peak, the payables somewhat retraced but remained relatively elevated, fluctuating between $8,174 million and $10,443 million through mid-2023.

From late 2023 through mid-2025, accounts payable figures oscillate around the $9,000 million mark with some variance but no clear directional trend. This suggests periods of increased procurement or credit terms extension but stabilizing somewhat after the earlier peak.

Payables Turnover Ratio

The payables turnover ratio data, available from December 2020 onward, demonstrates variability across quarterly periods with values generally ranging from about 2.66 to 3.38. After a peak at 3.38 in September 2021, the ratio dips to lows near 2.66 and later rebounds to values above 3.0 intermittently.

These fluctuations suggest changes in the pace at which the company settles its accounts payable relative to cost of products sold. Periods of lower payables turnover could indicate slower payment cycles or extended credit terms, whereas higher ratios imply faster payment or better cash management.

Overall, the data indicates that while the cost of products sold exhibits some cyclical variability, it remains within a bounded range without strong acceleration or reduction over the multi-year period. Accounts payable shows consistent but fluctuating growth with peaks and partial retracements, reflective of operational or market conditions affecting supplier credit. The payables turnover ratio reflects varying payment velocity patterns but generally remains around a stable average slightly above 3, signaling consistent credit management practices.


Working Capital Turnover

Johnson & Johnson, working capital turnover calculation (quarterly data)

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Current assets 54,498 71,551 55,893 53,249 57,817 57,002 53,495 53,703 60,567 64,388 55,294 65,236 63,847 60,424 60,979 59,889 53,769 52,533 51,237 57,578 45,892 44,226
Less: Current liabilities 54,180 56,903 50,321 51,759 53,933 48,725 46,282 44,370 54,170 60,373 55,802 45,543 44,821 43,390 45,226 44,561 38,721 40,932 42,493 38,847 36,772 33,689
Working capital 318 14,648 5,572 1,490 3,884 8,277 7,213 9,333 6,397 4,015 (508) 19,693 19,026 17,034 15,753 15,328 15,048 11,601 8,744 18,731 9,120 10,537
 
Sales to customers 23,743 21,893 22,520 22,471 22,447 21,383 21,395 21,351 21,519 20,894 23,706 23,791 24,020 23,426 24,804 23,338 23,312 22,321 22,475 21,082 18,336 20,691
Short-term Activity Ratio
Working capital turnover1 284.99 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 4.88 5.02 5.57 5.95 5.97 5.93 7.26 9.44
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc. 130.12
Amgen Inc. 8.36 5.40 4.83 5.19 3.39 2.25 0.81 0.84 0.82 3.82 2.52 3.67 4.34 3.37 2.55 5.35 2.84 2.55
Bristol-Myers Squibb Co. 8.09 6.87 7.79 8.49 12.50 15.56 4.60 10.47 5.53 5.55 8.30 5.75 4.92 6.24 3.95 4.43 4.24 4.25 3.72
Danaher Corp. 5.71 8.27 8.85 8.73 8.10 3.60 4.22 2.18 3.08 3.81 4.20 5.00 5.43 5.91 8.40 7.98 3.12 3.45 3.48
Eli Lilly & Co. 4.38 10.32 6.06 12.62 5.45 31.79 12.21 5.77 31.84 14.71 19.45 8.19 8.33 6.73 12.14 5.21 4.93
Gilead Sciences Inc. 6.27 3.99 9.22 17.98 26.58 5.61 6.74 84.15 9.14 8.42 8.56 6.87 6.68 8.54 7.25 7.09 7.06 5.30
Merck & Co. Inc. 6.19 6.19 5.86 5.14 9.68 9.29 6.69 8.86 5.63 5.16 5.58 6.39 6.09 7.62 6.51 6.97 84.97 109.83
Pfizer Inc. 6.64 8.64 5,036.00 29.17 1.62 2.03 6.89 11.00 3.83 5.05 6.10 4.78 4.29 4.21 3.60 4.58
Regeneron Pharmaceuticals Inc. 1.01 0.97 0.88 0.87 0.86 0.82 0.87 0.92 0.90 0.96 1.09 1.14 1.46 1.59 1.35 1.29 1.35 1.20
Thermo Fisher Scientific Inc. 4.20 4.87 4.61 3.96 4.38 4.05 4.86 7.40 10.13 5.46 5.40 6.03 6.13 5.87 2.30 3.10 3.36 2.76
Vertex Pharmaceuticals Inc. 1.78 1.83 1.82 1.92 1.07 0.93 0.87 0.90 0.93 0.85 0.90 0.93 0.97 1.02 1.03 1.01 0.97 0.99

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q2 2025 Calculation
Working capital turnover = (Sales to customersQ2 2025 + Sales to customersQ1 2025 + Sales to customersQ4 2024 + Sales to customersQ3 2024) ÷ Working capital
= (23,743 + 21,893 + 22,520 + 22,471) ÷ 318 = 284.99

2 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals several notable trends in key financial metrics over the periods under review.

Working Capital
Working capital values exhibit considerable volatility through the periods. Initially, there is an increase from 10,537 million USD in March 2020 to a peak of 18,731 million USD by September 2020, followed by a sharp decline to 8,744 million USD by December 2020. Subsequently, there is a generally positive trend with fluctuations, reaching another high of 19,693 million USD in October 2022. However, there is a pronounced dip to negative working capital (-508 million USD) in December 2022, signaling potential liquidity strain at that point. Post this period, working capital rebounds variably, ending with a significantly low value of 318 million USD in June 2025 after a spike to 14,648 million USD in March 2025. This pattern indicates inconsistent working capital management or seasonal/business cycle effects.
Sales to Customers
Sales figures present a relatively stable and gradually increasing trend with mild fluctuations. Starting at 20,691 million USD in March 2020, sales experience a slight dip in mid-2020 but recover by December 2020 to 22,475 million USD. The sales maintain a range mostly between 21,000 and 24,000 million USD over subsequent periods, peaking at 24,804 million USD in December 2021, and fluctuating around this mark through the subsequent quarters. The data reflects steady revenue generation capacity without sharp declines or rapid growth phases in the observed period.
Working Capital Turnover Ratio
The working capital turnover ratio shows notable irregularities and extreme values, suggesting variability in either sales efficiency or working capital levels. The ratio starts around 9.44 in September 2020 and decreases gradually through 2021 to about 4.88 by October 2022, indicative of decreasing sales relative to working capital. A remarkable surge is observed after gaps in reporting, with the ratio moving sharply up to 23.02 in April 2023 and displaying volatile spikes thereafter, including an exceptionally high value of 284.99 in June 2025. These spikes likely correlate with periods of very low or negative working capital, producing disproportionate ratio values and signaling potential short-term imbalances between operational liquidity and sales activity.

In summary, sales maintain a stable upward trajectory with minor fluctuations, while working capital shows significant variability including periods of negative values. The working capital turnover ratio’s volatility reflects these underlying working capital fluctuations and highlights possible operational or financial management challenges requiring further investigation. The data suggests a need to monitor liquidity closely given the observed working capital dips and the implications on operational efficiency.


Average Inventory Processing Period

Johnson & Johnson, average inventory processing period calculation (quarterly data)

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data
Inventory turnover 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77 2.87 2.86 2.91 2.86 3.04
Short-term Activity Ratio (no. days)
Average inventory processing period1 168 163 165 169 166 158 154 149 164 155 147 136 136 132 127 128 125 128 120
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. 98 90 89 75 75 73 77 85 81 75 66 73 74 65 63 67 68 79
Amgen Inc. 195 199 209 257 321 411 259 265 279 281 272 260 247 231 239 239 239 231
Bristol-Myers Squibb Co. 70 69 67 102 98 99 91 84 83 93 84 76 79 80 77 75 73 65 64
Danaher Corp. 101 96 88 101 102 98 96 104 102 104 91 96 98 94 88 90 85 84 85
Eli Lilly & Co. 379 329 349 316 312 298 261 267 268 237 196 204 189 194 204 203 217 265
Gilead Sciences Inc. 103 100 101 110 102 100 105 106 102 97 78 81 81 89 114 122 131 134
Merck & Co. Inc. 150 147 149 153 151 144 139 137 134 124 118 119 133 159 134 131 152 149
Pfizer Inc. 229 222 219 178 170 149 138 158 119 95 101 100 99 107 131 203 284 338
Regeneron Pharmaceuticals Inc. 582 572 573 562 553 519 508 532 549 562 440 379 287 292 415 445 653 625
Thermo Fisher Scientific Inc. 76 72 79 76 74 72 76 79 79 79 85 91 94 94 94 91 91 91
Vertex Pharmaceuticals Inc. 320 287 267 238 222 214 213 192 177 156 136 135 129 143 142 145 142 139

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q2 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 2.17 = 168

2 Click competitor name to see calculations.


Inventory Turnover
The inventory turnover ratio exhibits a generally declining trend over the analyzed periods. Beginning at 3.04, it decreases steadily to 2.17 by the last recorded period. This decline suggests that the company is turning over its inventory less frequently over time, which may indicate slower sales or accumulation of inventory relative to sales.
Average Inventory Processing Period
The average inventory processing period shows an increasing trend across the same time frame. Starting at 120 days, it rises consistently to reach as high as 168 days toward the end of the period. This increase in days corresponds inversely with the falling inventory turnover ratio, indicating that inventory is held longer before being sold or processed.
Relationship Between Metrics
The inverse relationship between inventory turnover and average inventory processing period is apparent throughout the dataset. As the inventory turnover decreases, the average processing period for inventory lengthens. This pattern reinforces the conclusion that inventory management has become less efficient with respect to turnover during the reported timeframe.
Operational Implications
The declining turnover ratio along with the increasing inventory processing period could raise concerns regarding cash flow and working capital management. Extended holding periods may indicate potential overstocking, obsolescence risks, or decreased demand for products. These trends may warrant closer examination of supply chain and sales strategies to improve inventory efficiency.

Average Receivable Collection Period

Johnson & Johnson, average receivable collection period calculation (quarterly data)

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data
Receivables turnover 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08 6.14 6.13 6.00 5.64 6.08
Short-term Activity Ratio (no. days)
Average receivable collection period1 72 65 61 67 67 64 64 62 68 65 62 60 62 60 59 60 61 65 60
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 79 71 75 78 80 75 76 75 74 71 68 72 69 65 61 67 70 70
Amgen Inc. 91 77 86 86 88 99 88 84 84 82 79 79 76 74 71 68 67 68
Danaher Corp. 54 54 54 54 51 52 60 59 55 53 57 51 54 53 57 55 56 58 66
Eli Lilly & Co. 90 89 92 103 80 97 93 93 99 88 84 80 79 86 78 80 80 87
Gilead Sciences Inc. 56 56 59 62 62 63 64 57 57 65 59 55 51 61 61 58 57 73
Merck & Co. Inc. 62 58 66 68 68 63 64 69 66 58 59 62 66 69 66 61 65 60
Pfizer Inc. 69 66 87 74 72 69 58 48 48 40 59 55 52 52 63 70 78 69
Regeneron Pharmaceuticals Inc. 144 160 161 155 146 158 156 148 151 160 148 132 107 137 147 206 166 177
Thermo Fisher Scientific Inc. 72 70 71 68 68 70 70 67 66 66 63 66 70 74 52 52 56 65
Vertex Pharmaceuticals Inc. 59 53 60 58 64 58 58 60 61 59 58 58 59 55 56 51 56 52

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q2 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 5.08 = 72

2 Click competitor name to see calculations.


The receivables turnover ratio exhibits a fluctuating but generally declining trend over the analyzed periods. Beginning at 6.08, the ratio decreases to a low of approximately 5.36, followed by intermittent increases and decreases, ending lower at 5.08 by the final period. This suggests a slight deterioration in the efficiency of receivables collection over time, implying that the company is turning over its receivables less frequently as time progresses.

Correspondingly, the average receivable collection period, measured in number of days, shows a complementary trend. Starting from 60 days, the collection period increases to a peak of 68 days, with some fluctuations throughout the periods, and culminating at 72 days by the end of the observation window. This increase indicates that, on average, it takes more time for the company to collect its outstanding receivables, reinforcing the interpretation of a lengthening cash conversion cycle.

The inverse relationship between these two metrics is consistent with standard financial principles. As the receivables turnover ratio decreases, the average collection period generally rises. This dynamic can have implications on the company’s liquidity and working capital management. The observed patterns suggest that the company may need to evaluate its credit policies or collection processes to enhance cash flow efficiency.


Operating Cycle

Johnson & Johnson, operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data
Average inventory processing period 168 163 165 169 166 158 154 149 164 155 147 136 136 132 127 128 125 128 120
Average receivable collection period 72 65 61 67 67 64 64 62 68 65 62 60 62 60 59 60 61 65 60
Short-term Activity Ratio
Operating cycle1 240 228 226 236 233 222 218 211 232 220 209 196 198 192 186 188 186 193 180
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. 177 161 164 153 155 148 153 160 155 146 134 145 143 130 124 134 138 149
Amgen Inc. 286 276 295 343 409 510 347 349 363 363 351 339 323 305 310 307 306 299
Danaher Corp. 155 150 142 155 153 150 156 163 157 157 148 147 152 147 145 145 141 142 151
Eli Lilly & Co. 469 418 441 419 392 395 354 360 367 325 280 284 268 280 282 283 297 352
Gilead Sciences Inc. 159 156 160 172 164 163 169 163 159 162 137 136 132 150 175 180 188 207
Merck & Co. Inc. 212 205 215 221 219 207 203 206 200 182 177 181 199 228 200 192 217 209
Pfizer Inc. 298 288 306 252 242 218 196 206 167 135 160 155 151 159 194 273 362 407
Regeneron Pharmaceuticals Inc. 726 732 734 717 699 677 664 680 700 722 588 511 394 429 562 651 819 802
Thermo Fisher Scientific Inc. 148 142 150 144 142 142 146 146 145 145 148 157 164 168 146 143 147 156
Vertex Pharmaceuticals Inc. 379 340 327 296 286 272 271 252 238 215 194 193 188 198 198 196 198 191

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q2 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 168 + 72 = 240

2 Click competitor name to see calculations.


Average Inventory Processing Period
The average inventory processing period exhibits a generally increasing trend throughout the observed quarters. Starting at 120 days in early 2021, this period gradually extended to 168 days by mid-2025. There are noticeable increments particularly between early 2023 and mid-2025, with minor fluctuations occurring around late 2023. This suggests a lengthening time to process inventory over time, potentially indicating changes in inventory management or supply chain dynamics.
Average Receivable Collection Period
The average receivable collection period shows more variability but maintains an overall upward trajectory. From 60 days in early 2021, the period fluctuated moderately, reaching a peak of 72 days by mid-2025. Some shorter intervals are observed, particularly in late 2023 and mid-2024, but the general pattern indicates a gradual extension in the duration to collect receivables, which could impact cash flow efficiency.
Operating Cycle
The operating cycle, combining inventory processing and receivable collection periods, follows a clear rising trend over the quarters. It increases from 180 days in early 2021 to 240 days by mid-2025. The expansion in the operating cycle is consistent with the increases in both inventory and receivable collection periods, reflecting a lengthening overall time required to complete the full operating process from inventory acquisition to receivable collection. This trend may imply higher capital tied up in operations and potentially slower turnover rates.

Average Payables Payment Period

Johnson & Johnson, average payables payment period calculation (quarterly data)

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data
Payables turnover 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26 2.70 3.32 3.38 3.34 2.99
Short-term Activity Ratio (no. days)
Average payables payment period1 119 123 137 120 121 113 132 111 133 120 137 118 116 112 135 110 108 109 122
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc. 70 54 61 73 60 69 70 64 73 90 69 72 78 77 67 74 83 84
Bristol-Myers Squibb Co. 140 104 94 106 120 117 111 97 108 114 109 96 107 112 108 94 123 99 84
Danaher Corp. 65 66 66 60 63 62 65 65 63 64 67 65 73 72 82 70 66 69 76
Eli Lilly & Co. 140 140 135 142 127 134 130 138 119 106 86 87 70 83 82 85 97 107
Gilead Sciences Inc. 43 49 49 29 34 31 37 40 41 58 33 31 32 39 40 42 42 67
Merck & Co. Inc. 92 98 86 83 81 89 80 80 84 89 71 75 86 123 80 93 96 108
Pfizer Inc. 110 115 99 79 87 98 72 93 76 72 66 59 55 66 71 98 136 181
Regeneron Pharmaceuticals Inc. 129 146 94 110 137 122 106 116 136 138 98 91 68 84 86 107 164 155
Thermo Fisher Scientific Inc. 44 45 38 37 37 41 35 34 39 48 37 41 46 53 44 41 45 49
Vertex Pharmaceuticals Inc. 105 98 98 85 96 106 117 115 107 103 44 73 66 79 54 57 61 77

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q2 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 3.07 = 119

2 Click competitor name to see calculations.


The payables turnover ratio exhibits fluctuations over the observed periods, with values ranging approximately between 2.66 and 3.38. Initially, following the earliest recorded data point at 2.99, the ratio increased to a peak of 3.38 before experiencing a general decline to around 2.66 in later periods. This variability suggests periods of both faster and slower turnover of payables, indicating changes in the company's payment practices or supplier credit terms over time.

Correspondingly, the average payables payment period, expressed in days, displays an inverse pattern relative to the payables turnover ratio. The shortest payment period recorded is approximately 108 days, while the longest reaches up to 137 days. Periods of higher payables turnover coincide with reduced payment periods, and vice versa, highlighting typical financial behavior where quicker payables turnover aligns with shortened payment cycles.

Notably, there are intervals where the average payment period lengthens significantly, especially when the payables turnover ratio dips below 3.0. This indicates that the company may be extending its payment terms during those times, potentially to manage cash flow or renegotiate supplier agreements. Conversely, increases in turnover ratio and decreases in payment days suggest periods of more prompt payables settlement.

Overall, the data reveal cyclical shifts in payables management, reflecting dynamic operational or strategic adjustments. The company appears to balance its payment timing, alternating between longer credit terms and quicker settlements, possibly in response to internal cash management priorities or external market conditions.


Cash Conversion Cycle

Johnson & Johnson, cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data
Average inventory processing period 168 163 165 169 166 158 154 149 164 155 147 136 136 132 127 128 125 128 120
Average receivable collection period 72 65 61 67 67 64 64 62 68 65 62 60 62 60 59 60 61 65 60
Average payables payment period 119 123 137 120 121 113 132 111 133 120 137 118 116 112 135 110 108 109 122
Short-term Activity Ratio
Cash conversion cycle1 121 105 89 116 112 109 86 100 99 100 72 78 82 80 51 78 78 84 58
Benchmarks
Cash Conversion Cycle, Competitors2
Amgen Inc. 216 222 234 270 349 441 277 285 290 273 282 267 245 228 243 233 223 215
Danaher Corp. 90 84 76 95 90 88 91 98 94 93 81 82 79 75 63 75 75 73 75
Eli Lilly & Co. 329 278 306 277 265 261 224 222 248 219 194 197 198 197 200 198 200 245
Gilead Sciences Inc. 116 107 111 143 130 132 132 123 118 104 104 105 100 111 135 138 146 140
Merck & Co. Inc. 120 107 129 138 138 118 123 126 116 93 106 106 113 105 120 99 121 101
Pfizer Inc. 188 173 207 173 155 120 124 113 91 63 94 96 96 93 123 175 226 226
Regeneron Pharmaceuticals Inc. 597 586 640 607 562 555 558 564 564 584 490 420 326 345 476 544 655 647
Thermo Fisher Scientific Inc. 104 97 112 107 105 101 111 112 106 97 111 116 118 115 102 102 102 107
Vertex Pharmaceuticals Inc. 274 242 229 211 190 166 154 137 131 112 150 120 122 119 144 139 137 114

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q2 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 168 + 72119 = 121

2 Click competitor name to see calculations.


The analysis of the financial timing metrics over the presented periods reveals several noteworthy trends. The average inventory processing period has generally exhibited an upward trajectory from 120 days initially recorded to 168 days by the final period. This indicates a gradual lengthening in the time inventory is held before being converted into sales, possibly implying inventory management challenges or strategic holding of stock.

The average receivable collection period shows moderate fluctuations. Starting around 60 days, it experienced some increases and decreases but exhibited a tendency to rise towards the later periods, reaching up to 72 days. This suggests a slight elongation in the company's credit collection process, which could have implications for cash inflows and working capital management.

For the average payables payment period, the values demonstrate considerable volatility without a clear persistent trend. Initially around 122 days, it dropped to near 108 days mid-series, then increased again with peaks surpassing 130 days before settling around the 119-day mark towards the end. This variability may reflect changes in payment policies, supplier negotiations, or cash management strategies over time.

The cash conversion cycle, which integrates the inventory processing period, receivables, and payables, shows considerable variation. It initially ranged around 58 days, climbed up to peaks of approximately 121 days, reflecting periods when cash was tied up longer in the operating cycle. These fluctuations indicate uneven patterns in operational efficiency and liquidity management throughout the periods reviewed.

Inventory Processing Period
Increased from 120 days to 168 days, indicating slower inventory turnover over time.
Receivable Collection Period
Fluctuated but generally increased from 60 to 72 days, suggesting slower collections from customers.
Payables Payment Period
Varied without a clear trend, ranging between approximately 108 and 137 days, implying changes in payment practices.
Cash Conversion Cycle
Varied significantly, increasing from 58 to as high as 121 days, reflecting fluctuations in cash tied up in operations.

In summary, the data depicts a lengthening in the working capital cycle, primarily driven by longer inventory holding and receivables collection periods, despite fluctuating payment practices to suppliers. These patterns suggest increasing capital requirements to sustain operations and highlight areas where efficiency improvements could enhance liquidity and operational performance.